Potential for drug-drug interactions between antiretrovirals and HCV direct acting antivirals in a large cohort of HIV/HCV coinfected patients

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Poizot Martin, Isabelle ^a,b   Naqvi, Alissa ^c   Obry Roguet, Véronique ^a   Valantin, Marc Antoine ^d,e   Cuzin, Lise ^f,g,h   Billaud, Eric ⁱ   Cheret, Antoine ^j,k,l   Rey, David ^m   Jacomet, Christine ⁿ   Duvivier, Claudine ^l,o   Pugliese, Pascal ^c   Pradat, Pierre ^p,q   Cotte, Laurent ^p,q   Bregigeon S ^r   Faucher, O ^r   Obry Roguet, V ^r   Orticoni, M ^r   Soavi, M J ^r   Luquet Besson, I ^r   Ressiot, E ^r   Pinot, I ^r   Ducassou, M J ^r   Bertone, H ^r   Galie, S ^r   Trijau, S ^r   Ritleng, A S ^r   Ivanova, A ^r   Guignard, M ^r   Cano, C E ^r   Poizot Martin, I ^r   Marchou, B ^r   Massip, P ^r   Bonnet, E ^r   Obadia, M ^r   Alvarez, M ^r   Porte, L ^r   Debard, A ^r   Cuzin, L ^r   Delobel, P ^r   Chauveau, M ^r   Garipuy, D ^r   Lepain, I ^r   Marcel, M ^r   Puntis, E ^r   Saune K ^r   Pugliese, P ^r   Ceppi, C ^r   Cua, E ^r   Cottalorda, J ^r   Dellamonica, P ^r   Demonchy, E ^r   Dunais, B ^r   Durant, J ^r   Etienne, C ^r   Ferrando, S ^r   Fuzibet, J G ^r   Garraffo, R ^r   Risso, K ^r   Mondain, V ^r   Naqvi, A ^r   more..

^a AIX MARSEILLE UNIVERSITY   (France)

^b AIX MARSEILLE UNIV   (France)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f Faculté de Médecine Centre Hospitalo universitaire   (France)

^g UNIVERSITÉ PAUL SABATIER   (France)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ HÔTEL DIEU   (France)

^j CENTRE HOSPITALIER DE TOURCOING   (France)

^k BICÊTRE HOSPITAL   (France)

^l HÔPITAL NECKER ENFANTS MALADES   (France)

^m UNIVERSITY HOSPITAL OF STRASBOURG   (France)

ⁿ UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^o INSTITUT PASTEUR   (France)

^p CROIX ROUSSE HOSPITAL   (France)

^q CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^r Inserm U1052 ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; DARUNAVIR; DASABUVIR; DIDANOSINE; DIRECT ACTING ANTIVIRAL AGENT; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; LAMIVUDINE; LEDIPASVIR PLUS SOFOSBUVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; TENOFOVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIBODY; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPATITIS C ANTIBODY; PROTEINASE INHIBITOR;

ADULT; ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; PRESCRIPTION; SIMULATION; VIRUS LOAD; ADVERSE EFFECTS; COINFECTION; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG INTERACTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; PHYSIOLOGY;

ANTI-HIV AGENTS; COINFECTION; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS;

EID: 84949818279     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0141164     Document Type: Article

References (34)

1. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS. 2011; 6(6):478-82. Epub 2011/10/18. doi: 10.1097/COH.0b013e32834bd365 01222929-201111000-00007 [pii]. PMID: 22001892; PubMed Central PMCID: PMC3293393.
2. Cacoub P, Dabis F, Costagliola D, Almeida K, Lert F, Piroth L, et al. Burden of HIV and hepatitis C coinfection: the changing epidemiology of hepatitis C in HIV-infected patients in France. Liver Int. 2015; 35(1):65-70. Epub 2014/07/22. doi: 10.1111/liv.12639 PMID: 25040895.
3. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001; 33(4):562-9. Epub 2001/07/20. CID001179 [pii] doi: 10.1086/321909 PMID: 11462196.
4. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008; 22(15):1979-91. Epub 2008/09/12. doi: 10.1097/QAD.0b013e32830e6d51 00002030-200810010-00010 [pii]. PMID: 18784461.
5. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 2011; 8(1):12-22. Epub 2011/01/12. doi: 10.1007/s11904-010-0071-3 PMID: 21221855; PubMed Central PMCID: PMC3035774.
6. Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, et al. Telaprevir for HIV-HCV coinfected patients failing peginterferon-ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial. Clin Infect Dis (In Press). 2014. doi: 10.1093/cid/ciu659 PMID: 25139963
7. Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis.2013; 13(7):597-605. Epub 2013/06/19. doi: 10.1016/S1473-3099(13)70149-X S1473-3099(13)70149-X [pii].PMID: 23768747.
8. Sulkowski MS, Sherman KE, Dieterich DT, Bsharat M, Mahnke L, Rockstroh JK, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med. 2013; 159(2):86-96. Epub 2013/05/21. doi: 10.7326/0003-4819-159-2-201307160-00654 1688398 [pii]. PMID: 23685940.
9. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370(20):1889-98. Epub 2014/04/15. doi: 10.1056/NEJMoa1402454 PMID: 24725239.
10. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368(1):34-44. Epub 2013/01/04.doi: 10.1056/NEJMoa1208953 PMID: 23281974.
11. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015. Epub 2015/04/04. S0140-6736(15)60159-3 [pii] doi: 10.1016/S0140-6736(15)60159-3 PMID: 25837829.
12. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384(9956):1756-65. Epub 2014/08/01. doi: 10.1016/S0140-6736(14) 61036-9 S0140-6736(14)61036-9 [pii]. PMID: 25078309.
13. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370 (3):211-21. Epub 2014/01/17. doi: 10.1056/NEJMoa1306218 PMID: 24428467.
14. Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015; 385(9973):1098-106. Epub 2015/02/11. doi: 10.1016/ S0140-6736(14)62483-1 S0140-6736(14)62483-1 [pii]. PMID: 25659285.
15. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015; 313(12):1232-9. Epub 2015/02/24. doi: 10.1001/jama.2015.1373 2173266 [pii]. PMID: 25706232.
16. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313(12):1223-31. Epub 2015/02/24. doi: 10.1001/jama.2015.1328 2173265 [pii]. PMID: 25706092.
17. AASLD, IDSA, IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org/full-report-view(visited September 1, 2015).
18. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015. Epub 2015/04/26. S0168-8278(15)00208-1 [pii] doi: 10.1016/j.jhep.2015.03.025 PMID: 25911336.
19. The University of Liverpool. http://www.hep-druginteractions.org/(visited June 5, 2015).
20. Karageorgopoulos DE, El-Sherif O, Bhagani S, Khoo SH. Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr Opin Infect Dis. 2014; 27(1):36-45. Epub 2013/12/07. doi: 10.1097/QCO.0000000000000034 PMID: 24305043.
21. Soriano V, Labarga P, Barreiro P, Fernandez-Montero JV, de Mendoza C, Esposito I, et al. Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015; 11(3):333-41. Epub 2015/01/03. doi: 10.1517/17425255.2015.998997 PMID: 25553890.
22. Pugliese P, Cuzin L, Cabie A, Poizot-Martin I, Allavena C, Duvivier C, et al. A large French prospective cohort of HIV-infected patients: the Nadis Cohort. HIV Med. 2009; 10(8):504-11. Epub 2009/06/03. doi: 10.1111/j.1468-1293.2009.00719.x HIV719 [pii]. PMID: 19486189.
23. Morlat P. Prise en charge médicale des personnes vivants avec le VIH. Actualisation 2014 du rapport 2013. http://www.sante.gouv.fr/prise-en-charge-medicale-des-personnes-vivant-avec-le-vih-actualisation-2014-du-rapport-2013.html (visited June 5, 2015).
24. Klein MB, Rollet KC, Hull M, Cooper C, Walmsley S, Conway B, et al. Who needs direct-acting antivirals for HCV? Challenges faced in advancing HCV therapy for HIV-HCV-coinfected individuals. Antivir Ther. 2013; 18(5):717-21. Epub 2012/12/06. doi: 10.3851/IMP2484 PMID: 23211632.
25. Beste LA, Ioannou GN. Prevalence and treatment of chronic hepatitis C virus infection in the US Department of Veterans Affairs. Epidemiol Rev. 2015; 37:131-43. Epub 2015/01/21. doi: 10.1093/epirev/mxu002 mxu002 [pii]. PMID: 25600415.
26. Cachay ER, Hill L, Wyles D, Colwell B, Ballard C, Torriani F, et al. The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS One. 2014; 9(7): e102883. Epub 2014/07/19. doi: 10.1371/journal.pone.0102883 PONE-D-14-18752 [pii]. PMID: 25036553; PubMed Central PMCID: PMC4103859.
27. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014; 9(7):e101554. Epub 2014/07/06. doi: 10.1371/journal.pone.0101554 PONE-D- 14-06670 [pii]. PMID: 24988388; PubMed Central PMCID: PMC4079454.
28. Grint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, et al. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med. 2013; 14 (10):614-23. Epub 2013/07/23. doi: 10.1111/hiv.12068 PMID: 23869664; PubMed Central PMCID: PMC4030620.
29. Kovari H, Ledergerber B, Cavassini M, Ambrosioni J, Bregenzer A, Stockle M, et al. High Hepatic and Extrahepatic Mortality and Low Treatment Uptake in HCV-coinfected Persons in the Swiss HIV Cohort Study between 2001 and 2013. J Hepatol. 2015. Epub 2015/05/06. S0168-8278(15)00302-5 [pii] doi: 10.1016/j.jhep.2015.04.019 PMID: 25937433.
30. Piroth L, Larsen C, Binquet C, Alric L, Auperin I, Chaix ML, et al. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study. Hepatology. 2010; 52(6):1915-21. Epub 2010/11/11. doi: 10.1002/hep.23959 PMID: 21064156.
31. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology. 2009; 136(5):1609-17. Epub 2009/05/08. PMID: 19422083; PubMed Central PMCID: PMC4260925.
32. Patel N, Nasiri M, Koroglu A, Amin R, McGuey L, McNutt LA, et al. Prevalence of drug-drug interactions upon addition of simeprevir- or sofosbuvir-containing treatment to medication profiles of patients with HIV and hepatitis C coinfection. AIDS Res Hum Retroviruses. 2015; 31(2):189-97. Epub 2014/11/30.doi: 10.1089/AID.2014.0215 PMID: 25432275.
33. Patel N, Nasiri M, Koroglu A, Bliss S, Davis M, McNutt LA, et al. A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients. Infect Dis Ther. 2015. Epub 2015/02/25. doi: 10.1007/s40121-015-0058-x PMID: 25708155; PubMed Central PMCID: PMC4363220.
34. Cope R, Pickering A, Glowa T, Faulds S, Veldkamp P, Prasad R. Majority of HIV/HCV Patients Need to Switch Antiretroviral Therapy to Accommodate Direct Acting Antivirals. AIDS Patient Care STDS. 2015; 29(7):379-83. Epub 2015/06/13. doi: 10.1089/apc.2015.0004 PMID: 26066094.